Researchers track Real-World use of leukemia drug blinatumomab
NCT ID NCT07117136
First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study gathers information from medical records of 200 adults with B-cell acute lymphoblastic leukemia who received the drug blinatumomab as part of their treatment. The goal is to see how many patients achieve complete remission and how long they survive. No new treatments are given; researchers simply observe and collect data from routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.